Ipsen Announces FDA Approval Of Dysport (Abobotulinumtoxina) For The Treatment Of Lower Limb Spasticity In Adults Post author:Sam Post published:June 15, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like 3 Biopharmas Worth Watching in 2018 January 14, 2018 Becton, Dickinson and Company Prices Offerings Of $2.25 Billion Of Common Stock And $2.25 Billion Of Depositary Shares Representing Interests In Mandatory Convertible Preferred Stock May 10, 2017 <b>Ideal Implant</b> Release: 6-Year Data On IDEAL IMPLANT Presented At The Annual Meeting Of The <b>American Society Of Plastic Surgery</b> In Orlando, FL October 8, 2017
Becton, Dickinson and Company Prices Offerings Of $2.25 Billion Of Common Stock And $2.25 Billion Of Depositary Shares Representing Interests In Mandatory Convertible Preferred Stock May 10, 2017
<b>Ideal Implant</b> Release: 6-Year Data On IDEAL IMPLANT Presented At The Annual Meeting Of The <b>American Society Of Plastic Surgery</b> In Orlando, FL October 8, 2017